Zehna Therapeutics is developing non-bacteriocidal small molecule inhibitors of a specific gut-microbial pathway that is clinically and mechanistically linked with chronic metabolic diseases; Chronic Kidney Disease (CKD) and Cardiovascular Disease (CVD).
Chronic Kidney Disease is our lead indication.
Our compounds inhibit the gut microbial enzyme CutC, preventing the conversion of dietary choline to trimethylamine and subsequently to trimethylamine N-oxide (TMAO) within the host. CutC is only present in bacterial cells, it is not present in eukaryotic cells or tissues.
High systemic levels of TMAO have been linked to accelerated development of both cardiovascular and chronic kidney disease, as demonstrated in CKD and CVD animal models and large-scale clinical cohort studies.
We have demonstrated statistically significant reduction in clinical markers of kidney function and fibrosis with one of our lead compounds in an adenine induced CKD animal model.
We are on track to be IND ready in 2024.
Our Series A raise will fund until end of 2025 and the inflection point of proof of principle in humans.
Chronic Kidney Disease is our lead indication.
Our compounds inhibit the gut microbial enzyme CutC, preventing the conversion of dietary choline to trimethylamine and subsequently to trimethylamine N-oxide (TMAO) within the host. CutC is only present in bacterial cells, it is not present in eukaryotic cells or tissues.
High systemic levels of TMAO have been linked to accelerated development of both cardiovascular and chronic kidney disease, as demonstrated in CKD and CVD animal models and large-scale clinical cohort studies.
We have demonstrated statistically significant reduction in clinical markers of kidney function and fibrosis with one of our lead compounds in an adenine induced CKD animal model.
We are on track to be IND ready in 2024.
Our Series A raise will fund until end of 2025 and the inflection point of proof of principle in humans.
Speaker
